Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma

December 2nd 2025

Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma

December 1st 2025

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 11/23

November 30th 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

November 28th 2025

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Dr Jakubowiak on the Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma

November 28th 2025

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R Myeloma

November 25th 2025

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Dr Raab on Safety and Infection Prophylaxis With Daratumumab-Based Induction Regimens in Myeloma

November 25th 2025

Marc S. Raab, MD, outlines the safety profile of teclistamab plus Dara-VRd in newly diagnosed multiple myeloma from the MajesTEC-5 trial.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

November 24th 2025

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Dr Jakubowiak on the Design of the Phase 3 ATLAS Trial in Multiple Myeloma

November 21st 2025

Andrzej Jakubowiak, MD, PhD, discusses the design of the phase 3 ATLAS trial in patients with newly diagnosed multiple myeloma after ASCT.

Modified Daratumumab-Based Quadruplet Shows Feasibility in Older Multiple Myeloma

November 19th 2025

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

Dr Raab on Patient Enrollment and the Design of the MajesTEC-5 Trial in NDMM

November 18th 2025

Marc S. Raab, MD, details the patient characteristics and design of the phase 2 MajesTEC-5 trial evaluating teclistamab in newly diagnosed multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 11/9

November 16th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Dr Jakubowiak on How the PERSEUS Study Informed the ATLAS Trial in Multiple Myeloma

November 13th 2025

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis

November 13th 2025

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

Community Administration of Bispecific Antibodies in Myeloma Hinges on Consensus and Guidance

November 13th 2025

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma

November 12th 2025

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.